DR. HAMZA OGLAT MD
Prescription History 1235650839
Internal Medicine - Interventional Cardiology in Des Moines, IA

NPI Status: Active since July 05, 2017

Contact Information

700 E UNIVERSITY AVE
DES MOINES, IA
ZIP 50316
Phone: (515) 263-5612

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. HAMZA OGLAT MD, an active Interventional Cardiology specialist practicing in Des Moines, IA. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 44 documented patient claims. Among these therapy options, the most frequently utilized medication is Clopidogrel, which accounts for 32 claims alone.

Medication Index

No matching medications currently found on file.

Brilinta

Generic Formulation: TicagrelorSpecialty: Interventional Cardiology
Provider Metrics Summary
Total Claims 12
30-Day Fills 32.0
Days Supply 960
IA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills37.1
Peer Average Days Supply1,060
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,326.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,193.87

State Avg Cost Per Claim

$584.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.

Therapeutic Applications

Ticagrelor is used along with low-dose aspirin to help prevent heart attack and stroke in people with a history of heart disease, stroke, or at increased risk for heart disease or stroke (for example, due to diabetes, history of transient ischemic attack-TIA). It may also prevent blood clots after certain heart surgeries (such as stent placement). Ticagrelor works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug. It keeps blood flowing smoothly in your body.

Clopidogrel

Generic Formulation: Clopidogrel BisulfateSpecialty: Interventional Cardiology
Provider Metrics Summary
Total Claims 32
30-Day Fills 90.0
Days Supply 2,700
IA State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills121.3
Peer Average Days Supply3,585
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $707.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.11

State Avg Cost Per Claim

$14.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.

Therapeutic Applications

Clopidogrel is used to prevent heart attacks and strokes in persons with heart disease (recent heart attack), recent stroke, or blood circulation disease (peripheral vascular disease). It is also used with aspirin to treat new/worsening chest pain (new heart attack, unstable angina) and to keep blood vessels open and prevent blood clots after certain procedures (such as cardiac stent). Clopidogrel works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug. It helps keep blood flowing smoothly in your body.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. HAMZA OGLAT MD provides transparency into local medical care patterns within Des Moines, IA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Interventional Cardiology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.